Charles River Laboratories Announces Strategic Acquisitions and Leadership Changes to Strengthen Drug Development Capabilities
Key Insights
Charles River Laboratories signed agreements to acquire K.F. (Cambodia) Ltd. (search) for approximately $510 million to strengthen its non-human primate supply chain, with the transaction expected to be accretive to non-GAAP earnings per share by $0.25 in 2026 and $0.60 in 2027.
The company exercised its option to acquire the remaining 79% stake in PathoQuest SAS (search) for approximately $60 million to enhance its next-generation sequencing capabilities for biopharmaceutical manufacturing quality-control testing.
Former FDA Deputy Principal Commissioner Dr. Namandjé Bumpus was appointed as Senior Vice President, Chief Scientific and Innovation Officer to lead the company's scientific strategy and advance new approach methodologies.
Charles River Laboratories International Inc. announced a series of strategic acquisitions and leadership changes at the J.P. Morgan 44th Annual Healthcare Conference, positioning the company to strengthen its drug development capabilities and supply chain security. The moves include two planned acquisitions totaling approximately $570 million and the appointment of a former FDA executive to drive scientific innovation.
Strategic Acquisition of Non-Human Primate Supplier
Charles River signed an agreement to acquire the assets of K.F. (Cambodia) Ltd. (search), a leading provider of non-human primates (NHPs) used in regulatory-required biomedical, pharmaceutical, and toxicological research. The $510 million acquisition is expected to close in early first quarter of 2026.
The strategic rationale centers on supply chain security for the company's Discovery and Safety Assessment (DSA) segment. Over the past two years, K.F. supplied Charles River with slightly above 30% of its globally sourced NHPs used in DSA operations. Combined with Noveprim (search), the company's Mauritius-based NHP supplier in which it holds a 90% controlling interest, the acquisition will enable Charles River to internally source most of its future annual NHP supply requirements.
"The planned K.F. acquisition will further strengthen and secure the supply chain for the Company's Discovery and Safety Assessment segment, and will also generate meaningful operating margin improvement through significant cost savings on NHP supply," the company stated.
While K.F. is not expected to generate significant third-party revenue, the transaction is projected to be accretive to non-GAAP earnings per share by approximately $0.25 in 2026 and $0.60 in 2027. The acquisition will provide greater oversight and operational control of a key supply source, including continued focus on biosecurity, regulatory compliance, and audit practices.
Expansion of Next-Generation Sequencing Capabilities
Charles River exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS (search), a Paris-based provider of next-generation sequencing (NGS) solutions for biopharmaceutical manufacturing quality-control testing. The purchase price for the remaining shares is expected to be €51.6 million or approximately $60 million, with closing anticipated by the end of the first quarter of 2026.
The company initially invested in PathoQuest in 2018, acquiring a 21% stake. Since 2016, Charles River has partnered with PathoQuest to provide clients access to NGS solutions that combine sequencing platforms with proprietary sample preparation and bioinformatics processes for animal-free viral safety testing, biopharmaceuticals characterization, and product release applications.
PathoQuest's innovative NGS approach supports Charles River's Alternative Methods Advancement Project (AMAP) initiative by utilizing new approach methodologies (NAMs) to replace animal use in viral safety workflows. The technology accelerates clients' quality-control testing timelines and the overall biologics development process.
PathoQuest's iDTECT (search)® quality-control assays provide comprehensive analysis for identifying adventitious agents while minimizing false negatives and offering genetic characterization of cell lines and viral vectors. The technology enhances safety testing for biologics including monoclonal antibodies (search), cell and gene therapies (search), vaccines (search), and recombinant proteins (search).
PathoQuest is expected to generate annual revenue of approximately $15 to $20 million in 2026. The transaction is not expected to have a material impact on Charles River's 2026 or 2027 GAAP or non-GAAP financial results.
Leadership Appointment Signals Innovation Focus
Charles River named Dr. Namandjé N. Bumpus as Senior Vice President, Chief Scientific and Innovation Officer. In this role, Dr. Bumpus will lead the company's scientific strategy, oversee research and development initiatives, and advance innovation to support clients in accelerating the drug development process.
Dr. Bumpus joined the Food and Drug Administration (FDA) in August 2022 as Chief Scientist and later served as the agency's Principal Deputy Commissioner until December 2024. Before joining the FDA, she was Professor and Director of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.
"The addition of Dr. Bumpus to drive our scientific innovation further supports this goal," said James C. Foster, Chair, President and Chief Executive Officer of Charles River Laboratories. "We are focused on continuing to lead the industry through advances in drug development."
Improved Market Conditions and 2026 Outlook
Charles River reported improved DSA demand trends throughout the second half of 2025, resulting in a preliminary estimate for the DSA net book-to-bill of approximately 1.1x in the fourth quarter of 2025. The sequential improvement from the third-quarter level was primarily driven by small and mid-sized biotechnology clients, while net bookings from global biopharmaceutical clients also increased.
For 2026, the company expects the top end of the guidance ranges for organic revenue growth will be at least flat for both its consolidated outlook and for the DSA segment. Foreign currency translation is expected to benefit the reported revenue growth rate by an incremental 100 to 150 basis points in 2026.
"We believe we are well positioned as we move into 2026 with a clear strategic direction, actions underway to unlock shareholder value, and are cautiously optimistic that the positive signs in the biopharmaceutical demand environment will continue this year," Foster concluded.
The company is cautiously optimistic that favorable demand trends will continue in 2026, resulting in expected DSA organic revenue growth in the second half of the year. An improvement in the Manufacturing Solutions segment's organic revenue growth rate in 2026 is expected to be offset by anticipated headwinds to Research Models and Services revenue related to the timing of NHP shipments and CRADL™ occupancy rates.